About Arcutis
Arcutis is a company based in Westlake Village (United States) founded in 2016 by Bhaskar Chaudhuri. Arcutis has raised $94.5 million across 1 funding round from investors including Goldman Sachs, BlackRock and Vivo Capital. The company has 342 employees as of December 31, 2024. Arcutis has completed 1 acquisition, including Ducentis BioTheapeutics. Arcutis offers products and services including ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234. Arcutis operates in a competitive market with competitors including LEO Pharma, Incyte, Formation Bio, DermBiont and Evommune, among others.
- Headquarter Westlake Village, United States
- Employees 342 as on 31 Dec, 2024
- Founders Bhaskar Chaudhuri
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arcutis Biotherapeutics, Inc.
-
Annual Revenue
$196.54 M (USD)229.74as on Dec 31, 2024
-
Net Profit
-$140.04 M (USD)46.58as on Dec 31, 2024
-
EBITDA
-$125.8 M (USD)47.41as on Dec 31, 2024
-
Total Equity Funding
$94.5 M (USD)
in 1 rounds
-
Latest Funding Round
$94.5 M (USD), Series C
Oct 17, 2019
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
342
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arcutis
Arcutis is a publicly listed company on the NASDAQ with ticker symbol ARQT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arcutis
Arcutis offers a comprehensive portfolio of products and services, including ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234.
Treats plaque psoriasis and other skin conditions through targeted inhibition.
Addresses seborrheic dermatitis and scalp issues with anti-inflammatory effects.
Develops potential treatments for dermatologic indications via PDE4 inhibition.
Targets additional skin diseases in the company's immuno-dermatology pipeline.
Focuses on novel therapies for chronic inflammatory skin disorders.
People of Arcutis
Unlock access to complete
Unlock access to complete
Sales and Marketing
64 people
Leadership Team
49 people
Software Development Team
14 people
Finance and Accounting
9 people
Senior Team
8 people
Operations Team
7 people
Advisor Team
5 people
Legal and Compliance
5 people
Unlock access to complete
Funding Insights of Arcutis
Arcutis has successfully raised a total of $94.5M through 1 strategic funding round. The most recent funding activity was a Series C round of $94.5 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arcutis
Arcutis has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, BlackRock and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked |
Investor details for Arcutis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arcutis
Arcutis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ducentis BioTheapeutics.
Investment portfolio details for Arcutis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Preclinical therapeutics for inflammatory and auto-immune diseases are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Arcutis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Arcutis
Detailed financials for Arcutis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arcutis Comparisons
Peer comparison for Arcutis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arcutis
Arcutis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LEO Pharma, Incyte, Formation Bio, DermBiont and Evommune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic options for chronic inflammatory disorders
|
Detailed competitors of Arcutis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arcutis
Complete news archive for Arcutis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arcutis
Arcutis was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Arcutis is headquartered in Westlake Village, United States. It is registered at Westlake Village, California, United States.
Frank Watanabe is the current CEO of Arcutis.
Arcutis is a funded company, having raised a total of $94.5M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Arcutis is 342.
Annual revenue of Arcutis is $196.54M as on Dec 31, 2024.
Arcutis was founded in 2016 and is headquartered in Westlake Village, United States. Focus is placed on the development of immunotherapeutics targeting dermatology. Key products include topical roflumilast formulations for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis, along with ARQ-252 cream as a JAK1 inhibitor for hand eczema and vitiligo, and ARQ-255 for alopecia areata. Operations center on advancing these topical treatments within the biopharmaceutical sector.
Arcutis's top competitors include LEO Pharma, Formation Bio and Incyte.
Arcutis offers ZORYVE cream, ZORYVE foam, ARQ-252, ARQ-255, and ARQ-234.
Yes, Arcutis is publicly traded on NASDAQ under the ticker symbol ARQT.
Arcutis has made 1 acquisition, including Ducentis BioTheapeutics.
Arcutis has 6 investors. Key investors include Goldman Sachs, BlackRock, Vivo Capital, HBM Partners, and Omega Funds.
The ticker symbol of Arcutis is ARQT on NASDAQ.